INMB vs PSA · rev $50.0K vs rev $1.23B
INmune Bio Inc (INMB) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
INmune Bio Inc (INMB) is a biotechnology company listed on US.
PSA (PSA) common stock.
Latest reported INMB revenue for 2025-09-30 was $50.0K. Net income was -$6.5M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. INMB currently screens at market cap $33.5M.
Latest reported PSA revenue for 2026-06-30 was $1.23B. Net income was $500.0M. Revenue was up 1.2% from 2026-03-31 to 2026-06-30. PSA currently screens at market cap $0.
INMB currently screens at market cap $33.5M. PSA currently screens at market cap $0.
Not investment advice. Open the INMB and PSA stock pages for the full models.
Not investment advice.